CN107693546A - A kind of medicine containing American cockroach and Sorafenib and its application - Google Patents
A kind of medicine containing American cockroach and Sorafenib and its application Download PDFInfo
- Publication number
- CN107693546A CN107693546A CN201611174194.2A CN201611174194A CN107693546A CN 107693546 A CN107693546 A CN 107693546A CN 201611174194 A CN201611174194 A CN 201611174194A CN 107693546 A CN107693546 A CN 107693546A
- Authority
- CN
- China
- Prior art keywords
- american
- cockroach
- sorafenib
- extract
- medicinal powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of medicine containing American cockroach and Sorafenib and its application, the active component of described medicine includes American cockroach and Sorafenib.Wherein, described American cockroach is American-cockroach-extract or American cockroach medicinal powder.Described medicine constituent can be 500~1000 parts of American-cockroach-extract by weight, 40~60 parts of Sorafenib；It can also be 300~500 parts of American cockroach medicinal powder, 40~60 parts of Sorafenib.The pharmaceutical composition of the present invention can effectively treat tumour, and positive effect is used alone better than American cockroach and Sorafenib, illustrate that the two has a synergistic function after being used cooperatively under present invention proportioning, potential applicability in clinical practice is good.
Description
Technical field
The invention belongs to pharmaceutical formulation field, it is especially useful in a kind of medicine containing American cockroach and Sorafenib and its should
With.
Background technology
Sorafenib is a kind of multi-kinase inhibitor, obtains the targeting medicine preferentially survived in liver cancer treatment as first
Thing, the treatment for liver cancer patient is determined by FDA Food and Drug Administration.
American cockroach (Periplaneta american) belongs to Insecta, Blattidae, is commonly called as cockroach.American cockroach is as medicine
With initially seeing《Sheng Nong's herbal classic》, for controlling bloody sputum disease, fever and chills, broken accumulation, laryngopharynx numbness, interior cold s.m.p.Sent out at present in research
Existing American cockroach ethanol extract is white to chronic marrow-derived leukocythemia (K562), promyelocytic leukemia (HL60), mouse in vitro
Blood disease (P388D1) cell line, nasopharyngeal carcinoma (CNE), lung cancer (A549), oral epithelium cancer (KB) cell line, oophoroma
(HO8910), cervical carcinoma (Hela) and prostate cancer (PC3) cell line, the cancer of the esophagus (Ecal09), sdenocarcinoma of stomach (BGC823), colon
Cancer (LS174T) cell line has growth inhibition effect.
Have not yet to see relevant report of the combination medicine of American cockroach and Sorafenib for treatment of cancer.
The content of the invention
The invention provides a kind of medicine containing American cockroach and Sorafenib, effect of the described medicine to treatment of cancer
Fruit is notable, and its action effect is substantially better than American cockroach and Sorafenib independent medication effect.
The active component of medicine of the present invention includes American cockroach and Sorafenib.
Wherein, described American cockroach is American-cockroach-extract or American cockroach medicinal powder or Kangfuxin Liquid.
Further, the active component of described medicine by weight, including：500~1000 parts of American-cockroach-extract,
40~60 parts of Sorafenib；Preferably, 1000 parts of American-cockroach-extract, 60 parts of Sorafenib.
American-cockroach-extract preparation method is as follows：
American cockroach, which crushes to be placed in ethanol, to be soaked, and refluxing extraction 2~3 times, is concentrated into no alcohol taste, obtains extract solution, past
Water is added in extract solution, after being well mixed, stands, cools down, filtering, be concentrated under reduced pressure, be drying to obtain；
Further, American-cockroach-extract of the present invention can be Kangfuxin Liquid, meet WS3-B-3674-2000
(Z) in the limit standard of the extract of polypide " American cockroach Peripleneta americana dry " also can, according to drying
Product calculate, and must not be less than 7.0% containing total amino acid, such as commercially available rehabilitation is new.
It is also possible that the active component of medicine is by weight, including：300~500 parts of American cockroach medicinal powder, Suo Lafei
40~60 parts of Buddhist nun；Preferably, 500 parts of American cockroach medicinal powder, 60 parts of Sorafenib.
American cockroach medicinal powder preparation method is：
A, adult bombay canary is placed in vacuum desiccator, it is 2~5% to be dried at 20~55 DEG C to water content, is obtained
Dry adult bombay canary；
B, it is -200 DEG C~-50 DEG C ultralow the adult bombay canary of the drying obtained in step a to be placed in into temperature setting
60~300 mesh are crushed in warm pulverizer, produce American cockroach medicinal powder.
Although selected in the specific embodiment of the invention through intestines and stomach absorbable preparation to embody the treatment of pharmaceutical composition effect
Fruit, however, this form of medication that can not be used to limit pharmaceutical composition of the present invention.With reference to modern separating and purifying technology or/and
Preparation means, those skilled in the art can also be prepared into transdermal absorption formulation, outer by American cockroach or its extract after purification
With other form of medication such as lotion, et al. Ke preparation, injections, so as to strengthen target-oriented drug, improve drug effect or avoid not
Necessary toxicity.
Present invention also offers a kind of compound formulation for the treatment of cancer, and it is as activity by American cockroach and Sorafenib
Composition, the preparation being prepared plus pharmaceutically acceptable auxiliary material or auxiliary element.
Described cancer includes：The cancer of the esophagus, nasopharyngeal carcinoma, breast cancer, incidence cancer, oophoroma, lung cancer, stomach cancer, Colon and rectum
Cancer, prostate cancer, cervical carcinoma, liver cancer, carcinoma of urinary bladder.
Pharmaceutically acceptable auxiliary material of the present invention, refer to the material being included in addition to the active ingredient (s in formulation, bag
Include but be not limited only to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, regulation
Agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc..Adhesive include syrup, Arabic gum, gelatin, sorbierite,
Tragacanth, cellulose and its derivates (such as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or hydroxypropyl methylcellulose
Element etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.；Filler include lactose, Icing Sugar, dextrin, starch and its
Derivative, cellulose and its derivates, inorganic calcium salt (such as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate), sorb
Alcohol or glycine etc.；Lubricant includes superfine silica gel powder, magnesium stearate, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, poly- second
Glycol etc.；Disintegrant includes starch and its derivative (such as sodium carboxymethyl starch, Explotab, pregelatinized starch, improvement shallow lake
Powder, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.；Wetting agent includes dodecyl sulphate
Sodium, water or alcohol etc.；Antioxidant packages are containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.；Bacteriostatic agent includes
0.5% phenol, 0.3% cresols, 0.5% anesin etc.；Conditioning agent includes hydrochloric acid, citric acid, potassium hydroxide (sodium), citron
Sour sodium and buffer (including sodium dihydrogen phosphate and disodium hydrogen phosphate) etc.；Emulsifying agent includes Tween-80, aliphatic acid sorb
Smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.；Solubilizer includes Tween-80, bile, glycerine etc..
The pharmaceutically acceptable complementary composition, it has certain physiologically active, but the addition of the composition will not change
Become the leading position of above-mentioned health products or pharmaceutical composition in treatment of diseases, and only play auxiliary effect, these are auxiliary
Assist effect is only the utilization to the composition known activity, is the usual adjuvant treatment modality of field of medicaments.
In above-mentioned preparation, the weight proportion of American-cockroach-extract and Sorafenib is (500~1000)：(40~60)；
Preferably, the weight proportion of American-cockroach-extract and Sorafenib is 1000：60.
Above-mentioned preparation can also be that the weight proportion of American cockroach medicinal powder and Sorafenib is (300~500)：(40~
60)；Preferably, the weight proportion of American cockroach medicinal powder and Sorafenib is 500：60.
Further, in the preparation, the content of the every big Lian extracts in daily unit formulation Central America and Sorafenib is total
Count 7.1g；The content of the every big Lian medicinal powder in daily unit formulation Central America and Sorafenib amounts to 3.7g." every daily unit dose
Amount " refers to the preparation total amount taken daily.
Embodiment
The preparation of the American-cockroach-extract of embodiment 1
American-cockroach-extract：500g American cockroaches, which crush to be placed in 90% ethanol, soaks 12h, refluxing extraction 2 at 85 DEG C
~3 times, no alcohol taste is concentrated into, obtains extract solution, 1500g water is added into extract solution, after being well mixed, is stood, cooling, mistake
Filter, it is concentrated under reduced pressure, dries, crushing and produce.
The preparation of the American cockroach medicinal powder of embodiment 2
American cockroach medicinal powder：Adult bombay canary is placed in vacuum desiccator, dried at 20~55 DEG C to water content
For 2%, dry adult bombay canary is obtained, it is -100 DEG C super that the adult bombay canary of obtained drying is placed in into temperature setting
60~300 mesh are crushed in Lowtemperaturepulverizer, produce American cockroach medicinal powder.
Embodiment 3
The medicine is American-cockroach-extract 1000mg and Sorafenib 60mg combination medicines in embodiment 1.
Embodiment 4
The medicine is American-cockroach-extract 500mg and Sorafenib 40mg combination medicines in embodiment 1.
Embodiment 5
The medicine is American-cockroach-extract 1000mg and Sorafenib 40mg combination medicines in embodiment 1.
Embodiment 6
The medicine is American-cockroach-extract 500mg and Sorafenib 60mg combination medicines in embodiment 1.
Embodiment 7
The medicine is American cockroach medicinal powder 500mg and Sorafenib 60mg combination medicines in embodiment 2.
Embodiment 8
The medicine is American cockroach medicinal powder 300mg and Sorafenib 40mg combination medicines in embodiment 2.
Embodiment 9
The medicine is American cockroach medicinal powder 500mg and Sorafenib 40mg combination medicines in embodiment 2.
Embodiment 10
The medicine is American cockroach medicinal powder 300mg and Sorafenib 60mg combination medicines in embodiment 2.
The combination medicine of American cockroach and Sorafenib described in any one of 3~embodiment of above example 10 can be with
Plus pharmaceutically conventional auxiliary material or complementary composition, capsule, tablet, sustained release is made according to technological means commonly used in the art
The oral formulations such as preparation, liquid preparation.
Beneficial effects of the present invention are proved below by way of specific pharmacodynamic experiment.Wherein, used in test example 1 and test example 2
American-cockroach-extract+Sorafenib composition be the medicine described in embodiment 3；U.S. used in test example 1 and test example 2
The big Lian medicinal powder+Sorafenib composition in continent is the medicine described in embodiment 7.
Test example 1
First, drug-induced HepG2 cell lines autophagocytosis of the present invention
1. experiment material
1.1 experimental cell
HepG2 cell lines (are provided) by preclinical medicine institute of Chengdu University of Traditional Chinese Medicine experimental center.With containing 10% tire
The RPMI 1640 culture mediums of cow's serum are placed in 37 DEG C, are cultivated in 5%CO2 constant temperature training case, are digested and passed with 0.25%EDTA pancreatin
Generation, growth period cell of taking the logarithm are tested.
1.2 experimental drugs and configuration
1.2.1 Sorafenib piece
Sorafenib (Bayer Bitterfeld GmbH medicines and health protection Co., Ltd).Take 1 (200mg) to be dissolved in 10ml DMSO solutions, match somebody with somebody
20mg/ml solution is made, is sterile filtered, -20 DEG C of refrigerators are kept in dark place.
1.3 experiment packet
Blank control group, American-cockroach-extract group, American cockroach medicinal powder group, Sorafenib group, American-cockroach-extract+
Sorafenib composition group, American cockroach medicinal powder+Sorafenib composition group
1.4 experimental method
1.4.1 to the influence of HepG2 cell inhibitory rates
Exponential phase HepG2 cells are configured to 2 × 104/ ml cell suspension, 96 orifice plates are added per the μ l of hole 200, point
For blank control group, Sorafenib group, American-cockroach-extract group, American cockroach medicinal powder group, American-cockroach-extract+Suo Lafei
Buddhist nun's group, American cockroach medicinal powder+Sorafenib group, every group sets 6 multiple holes.Each group adds corresponding pastille culture medium, be placed in 37 DEG C,
5%CO2After incubator is incubated culture 48h, using MTS, wavelength 450nm OD value (OD values) is determined on ELIASA, is counted
Inhibition rate of tumor cell (IR) is calculated, calculation formula is as follows.
IR (%)=(1- administration groups OD values/blank control group OD values) × 100%
1.4.2 to the influence of HepG2 apoptosis rates
By exponential phase HepG2 cell suspension inoculations in 6 orifice plates, it is big to be divided into blank control group, Sorafenib group, America
Lian extracts group, American cockroach medicinal powder group, American-cockroach-extract+Sorafenib group, American cockroach medicinal powder+Sorafenib group,
Every group sets 3 multiple holes.Each group adds corresponding pastille culture medium, is placed in 37 DEG C, 5%CO2Incubator is collected after being incubated culture 48h
Cell and with trypsin digestion adherent cell collecting in clear.According to Annexin V-FITC cell apoptosis detection kit explanations
Book, using flow cytomery Apoptosis situation.
1.4.3 to the influence of HepG2 cell cycles
By exponential phase HepG2 cell suspension inoculations in 6 orifice plates, it is big to be divided into blank control group, Sorafenib group, America
Lian extracts group, American cockroach medicinal powder group, American-cockroach-extract+Sorafenib group, American cockroach medicinal powder+Sorafenib group,
Every group sets 3 multiple holes.Each group adds corresponding pastille culture medium, is placed in 37 DEG C, 5%CO2Incubator digests receipts after being incubated culture 48h
Collect cell, illustrate according to cell cycle detection kit, it is 1 × 10 to wash cell adjustment cell concentration with PBS6/ml.Prepare
Single cell suspension is that 70% ethanol fixes 2h, 4 DEG C of preservations, using flow cytomery cell cycle stage with volume fraction.
1.4.4 to the influence of HepG2 cell LC3-II relative expression quantities
By exponential phase HepG2 cell suspension inoculations in 6 orifice plates, it is big to be divided into blank control group, Sorafenib group, America
Lian extracts group, American cockroach medicinal powder group, American-cockroach-extract+Sorafenib group, American cockroach medicinal powder+Sorafenib group,
Every group sets 3 multiple holes.Each group adds corresponding pastille culture medium, is placed in 37 DEG C, 5%CO2Incubator is incubated culture 48h.Take supernatant
With the protein concentration of BCA method determination samples, the significant albumen microtubule associated protein 1 of autophagosome film is detected using Western blot
The expression of light chain 3 (LC3-II), Image J softwares collect gray value, and phase is used for band gray value and internal reference gray value
To expression quantity.
1.5 statistical method
Using SPSS17.0 statistical softwares analyze, data information withRepresent, multigroup is compared from single factor test variance point
Analyse, compare two-by-two using independent samples t test in group, with P<0.05 is that difference has significant statistical significance.
2. result
The influence of 2.1 pairs of HepG2 cell inhibitory rates (IR)
Table 1 to HepG2 cell inhibitory rates influence (n=6,)
| Group | Dosage | OD values | IR (%) |
| Blank control group | - | 0.58±0.04 | - |
| Sorafenib group | 1.5μg/ml | 0.33±0.03* | 43.10 |
| American-cockroach-extract group | 25μg/ml | 0.45±0.05* | 22.41 |
| American cockroach medicinal powder group | 12.5μg/ml | 0.41±0.04* | 29.31 |
| American-cockroach-extract+Sorafenib group | 25μg/ml+1.5μmol/l | 0.29±0.0.01*△ | 50.00 |
| American cockroach medicinal powder+Sorafenib group | 12.5μg/ml+1.5μmol/l | 0.26±0.0.02*△ | 55.17 |
Note：Experimental group is compared with blank control group, * P ＜ 0.05；Experimental group is compared with Sorafenib group, △ P ＜ 0.05.
It was found from table one, compared with control group, each test group has inhibitory action to HepG2, and inhibiting rate is 22.41%~
55.17%, wherein American-cockroach-extract+Sorafenib group and American cockroach medicinal powder+Sorafenib group to HepG2 inhibiting rates more
Significantly, respectively 50.00% and 55.17%.
The influence of 2.2 pairs of HepG2 apoptosis rates
Table 2 to HepG2 apoptosis rates influence (n=3,)
| Group | Dosage | Apoptosis rate (%) |
| Blank control group | - | 4.6±3.96 |
| Sorafenib group | 1.5μg/ml | 42.87±4.23* |
| American-cockroach-extract group | 25μg/ml | 33.79±2.35* |
| American cockroach medicinal powder group | 12.5μg/ml | 39.68±2.63* |
| American-cockroach-extract+Sorafenib group | 25μg/ml+1.5μmol/l | 50.49±6.23* |
| American cockroach medicinal powder+Sorafenib group | 12.5μg/ml+1.5μmol/l | 56.90±6.90* |
Note：Experimental group is compared with blank control group, * P ＜ 0.05；Experimental group is compared with Sorafenib group, △ P ＜ 0.05.
It was found from table two, compared with blank group, each experimental group is high compared with blank control group to HepG2 apoptosis rate, is
33.79%~56.90%, there is statistical significance (P ＜ 0.5).Wherein American-cockroach-extract and American cockroach medicinal powder difference
It is more notable with two groups of apoptosis rate rises after Sorafenib drug combination, it is 50.49% and 56.90%.
The influence of 2.3 pairs of HepG2 cell cycles
The Sorafenib cell cycle of table 3 influence (n=3,)
Note：Experimental group is compared with blank control group, * P ＜ 0.05.
As can be seen from Table III, Sorafenib can make cell-cycle arrest in G0/G1 phases, up to 91.1%, with compareing
Group is compared and adds 52.72%.And American-cockroach-extract and American cockroach medicinal powder make cell block in the S phases.American cockroach carries
Take thing and American cockroach medicinal powder respectively with after Sorafenib drug combination, the G2 phases decline substantially, and cell major retardation is in G1 phases and S
Phase.
The influence of 2.4 pairs of HepG2 cell LC3-II relative expression quantities
Table 4 to HepG2 cell LC3-II relative expression quantities influence (n=3,)
| Group | Dosage | LC3-II |
| Blank control group | - | 0.04±0.00 |
| Sorafenib group | 1.5μg/ml | 0.26±0.02* |
| American-cockroach-extract group | 25μg/ml | 0.13±0.01* |
| American cockroach medicinal powder group | 12.5μg/ml | 0.20±0.01* |
| American-cockroach-extract+Sorafenib group | 25μg/ml+1.5μmol/l | 0.50±0.04*△ |
| American cockroach medicinal powder+Sorafenib group | 12.5μg/ml+1.5μmol/l | 0.56±0.02*△ |
Note：Experimental group is compared with blank control group, * P ＜ 0.05；Experimental group is compared with Sorafenib group, △ P ＜ 0.05.
As can be seen from Table IV, compared with blank control group, LC3-II is raised after the effect of each experimental group, has statistics
Learn meaning (P ＜ 0.5).Wherein American-cockroach-extract and American cockroach medicinal powder are more aobvious with Sorafenib drug combination effect respectively
Write.
Test example 2
2nd, to the research of tumor-bearing mice
1. experiment material
1.1 experimental animal
BALB/C nude mices, SPF levels, 4~5 week old, 15~17g of body weight, nude mice are raised under Clean Facility, constant temperature (24
~26 DEG C), cage tool, bedding and padding, drinking water and feed are sterile-processed, and experimenter strictly carries out sterile working.
1.2 experimental cell
HepG2 cell lines (are provided) by preclinical medicine institute of Chengdu University of Traditional Chinese Medicine experimental center.
1.3 experimental drugs and configuration
Sorafenib (Bayer Bitterfeld GmbH medicines and health protection Co., Ltd).
1.4 experimental method
1.4.1 Nude Mouse Model is established
Human hepatoma HepG2 cell's strain is subjected in vitro culture to exponential phase, collects single cell suspension into centrifuge tube.
1000rpm/min centrifuges 5min, abandoning supernatant, and PBS is resuspended after washing 2 times with PBS, is configured to 1.5 × 107Individual/ml, naked
Mouse dorsal sc is inoculated with HepG2 cell suspension 0.2ml, with vernier caliper measurement transplantable tumor most major diameter (L) and most minor axis (W), presses
Formula V=L × W2× 0.52 calculates knurl volume.Treat that gross tumor volume reaches 100mm3Administration is grouped during left and right at random.
1.4.2 experiment packet and administration
BALB/C SPF levels nude mice 48 is used in experiment, is inoculated with human hepatoma HepG2 cell's suspension, treats that gross tumor volume reaches 100mm3
During left and right, nude mice is randomly divided into 6 groups, every group 8, i.e. blank control group, Sorafenib group, American-cockroach-extract group, U.S.
The big Lian medicinal powder group in continent, American-cockroach-extract+Sorafenib group, American cockroach medicinal powder+Sorafenib group.Blank control group is pressed
0.2ml/10g gavage physiological saline；Sorafenib group presses 60mg/kg gavage Sorafenibs；American-cockroach-extract presses 1000mg/
Kg gavage American-cockroach-extracts；American cockroach medicinal powder group presses 500mg/kg gavage American cockroach medicinal powder；Extracted by American cockroach
Thing+Sorafenib group presses 1000mg/kg+60mg/kg gavages American-cockroach-extract and Sorafenib respectively；American cockroach medicinal powder
+ Sorafenib group presses 500mg/kg+60mg/kg gavage American cockroach medicinal powder and Sorafenib respectively.Successive administration 28d, Yu Mo
Nude mice is put to death with cervical dislocation after secondary administration 48h, transplantable tumor is cut and records knurl weight, calculates tumour tumour inhibiting rate.
Tumour inhibiting rate (%)=(the average knurl weight of the average knurl weight-experimental group of blank control group) average knurl weight of/blank control group ×
100%
2. experimental result
The American cockroach medicinal powder of table 4, American-cockroach-extract and the two combine Sorafenib respectively
To tumour inhibiting rate influence (n=8,)
| Group | Dosage | Knurl weight (g) | Tumour inhibiting rate (%) |
| Control group | - | 0.623±0.192△ | - |
| Sorafenib group | 60mg/kg | 0.252±0.060* | 59.57 |
| American-cockroach-extract group | 1000mg/kg | 0.369±0.150*△ | 40.75 |
| American cockroach medicinal powder group | 500mg/kg | 0.342±0.110*△ | 45.10 |
| American-cockroach-extract+Sorafenib group | 1000mg/kg+60mg/kg | 0.187±0.097*△ | 70.02 |
| American cockroach medicinal powder+Sorafenib group | 500mg/kg+60mg/kg | 0.148±0.061*△ | 75.21 |
Note：Experimental group is compared with blank control group, * P ＜ 0.05；Experimental group is compared with Sorafenib group, △ P ＜ 0.05.
As can be seen from Table IV, compared with control group, each experimental group can reduce tumour inhibiting rate, and tumour inhibiting rate is 40.75%~
75.21%.Sorafenib and American-cockroach-extract composition medicine tumour inhibiting rate are apparently higher than American cockroach and Sorafenib list
Tumour inhibiting rate after private medicine；Sorafenib and American cockroach medicinal powder composition tumour inhibiting rate are apparently higher than American cockroach and Sorafenib
Tumour inhibiting rate after independent medication.By can be seen that Sorafenib is combined with American cockroach of the present invention in the data in upper table
Using treating cancer, the therapeutic action to tumour is substantially increased.
To sum up, the medicine of the present invention containing Sorafenib and American-cockroach-extract, for induced cancer cell
Autophagocytosis, tumour inhibiting rate are stronger than the effect that Sorafenib and American cockroach are used alone, and illustrate American cockroach and Sorafenib
There is obvious synergistic function after combination.Its drug combination ratio is：The weight of American-cockroach-extract and Sorafenib
Match as (500~1000)：(40~60)；The weight proportion of American cockroach medicinal powder and Sorafenib is (300~500)：(40~
60) there is good effect, it is preferred that American-cockroach-extract 1000mg, Sorafenib 60mg, if conversion adult's dosage
(assuming that the body weight of people is 60kg), every daily dosage of optimum proportioning of the present invention should be 7.1g；Another optimal proportion is America
Big Lian medicinal powder 500mg, Sorafenib 60mg, if conversion adult's dosage, every daily dosage of optimum proportioning of the present invention should be
3.7g。
Claims (10)
1. a kind of medicine containing American cockroach and Sorafenib, it is characterised in that the active component of described medicine includes U.S.
The big Lian in continent and Sorafenib；Wherein, described American cockroach is American-cockroach-extract or American cockroach medicinal powder.
2. medicine according to claim 1, it is characterised in that the active component of described medicine by weight, including：
500~1000 parts of American-cockroach-extract, 40~60 parts of Sorafenib；Preferably, 1000 parts of American-cockroach-extract, Suo Lafei
60 parts of Buddhist nun.
3. medicine according to claim 2, it is characterised in that the preparation method of described American-cockroach-extract is：It is beautiful
The big Lian in continent, which crushes to be placed in ethanol, to be soaked, and refluxing extraction 2~3 times, is concentrated into no alcohol taste, is obtained extract solution, adds into extract solution
Enter water, after being well mixed, stand, cool down, filtering, be concentrated under reduced pressure, be drying to obtain.
4. medicine according to claims 1 to 2, it is characterised in that the American-cockroach-extract is that rehabilitation is new.
5. medicine according to claim 1, it is characterised in that the active component of described medicine by weight, including：
300~500 parts of American cockroach medicinal powder, 40~60 parts of Sorafenib；Preferably, 500 parts of American cockroach medicinal powder, Sorafenib 60
Part.
6. medicine according to claim 5, it is characterised in that the preparation method of described American cockroach medicinal powder is：
A, adult bombay canary is placed in vacuum desiccator, it is 2~5% to be dried at 20~55 DEG C to water content, obtains drying
Adult bombay canary；
B, the adult bombay canary of the drying obtained in step a is placed in the ultralow temperature powder that temperature setting is -200 DEG C~-50 DEG C
60~300 mesh are crushed in broken machine, produce American cockroach medicinal powder.
A kind of 7. compound formulation for the treatment of cancer, it is characterised in that it be by American cockroach and Sorafenib as active component,
The preparation being prepared plus pharmaceutically acceptable auxiliary material or auxiliary element, wherein, described American cockroach is American cockroach
Extract or American cockroach medicinal powder.
8. compound formulation according to claim 7, it is characterised in that the weight of American-cockroach-extract and Sorafenib is matched somebody with somebody
Than for (500~1000)：(40~60)；Preferably, the weight proportion of American-cockroach-extract and Sorafenib is 1000：60.
9. compound formulation according to claim 7, it is characterised in that the weight proportion of American cockroach medicinal powder and Sorafenib
For (300~500)：(40~60)；Preferably, the weight proportion of American cockroach medicinal powder and Sorafenib is 500：60.
10. compound formulation according to claim 7, it is characterised in that described cancer includes the cancer of the esophagus, nasopharyngeal carcinoma, breast
Gland cancer, incidence cancer, oophoroma, lung cancer, stomach cancer, colorectal cancer, prostate cancer, cervical carcinoma, liver cancer, carcinoma of urinary bladder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611174194.2A CN107693546A (en) | 2016-12-16 | 2016-12-16 | A kind of medicine containing American cockroach and Sorafenib and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611174194.2A CN107693546A (en) | 2016-12-16 | 2016-12-16 | A kind of medicine containing American cockroach and Sorafenib and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693546A true CN107693546A (en) | 2018-02-16 |
Family
ID=61169412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611174194.2A Pending CN107693546A (en) | 2016-12-16 | 2016-12-16 | A kind of medicine containing American cockroach and Sorafenib and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693546A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371914A (en) * | 2001-02-28 | 2002-10-02 | 刘耀北 | Cockroach polypeptide tracted from cockroach and extraction method thereof |
| CN1548058A (en) * | 2003-05-22 | 2004-11-24 | 福州金象中药制药有限公司 | Prepn process of alive adult roach extract |
| CN101057872A (en) * | 2007-03-20 | 2007-10-24 | 大理学院 | Anti tumor active part of American cockroach prepared with reverse phase material and medical application |
| CN101214262A (en) * | 2008-01-09 | 2008-07-09 | 大理学院 | American cockroaches effective fraction for anti-tumor prepared by macroporous adsorption resin and use |
| CN102988422A (en) * | 2012-08-23 | 2013-03-27 | 耿福能 | American cockroach nano extract and preparation method thereof |
| CN102988420A (en) * | 2012-08-23 | 2013-03-27 | 耿福能 | Nano periplaneta americana product as well as preparation method and application thereof |
| CN104586897A (en) * | 2014-12-29 | 2015-05-06 | 王帅 | Anti-cancer medicine |
| CN105878289A (en) * | 2015-07-06 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | Periplaneta americana preparation and applications thereof in preparing medicines for treating gastric cancer |
| CN105878290A (en) * | 2015-07-06 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | Periplaneta americana preparation and applications thereof in preparing medicines for treating colon cancer |
| CN105943558A (en) * | 2016-06-21 | 2016-09-21 | 四川好医生攀西药业有限责任公司 | Application of periplaneta americana in preparation of drug for preventing and treating radiation-induced damage |
-
2016
- 2016-12-16 CN CN201611174194.2A patent/CN107693546A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371914A (en) * | 2001-02-28 | 2002-10-02 | 刘耀北 | Cockroach polypeptide tracted from cockroach and extraction method thereof |
| CN1548058A (en) * | 2003-05-22 | 2004-11-24 | 福州金象中药制药有限公司 | Prepn process of alive adult roach extract |
| CN101057872A (en) * | 2007-03-20 | 2007-10-24 | 大理学院 | Anti tumor active part of American cockroach prepared with reverse phase material and medical application |
| CN101214262A (en) * | 2008-01-09 | 2008-07-09 | 大理学院 | American cockroaches effective fraction for anti-tumor prepared by macroporous adsorption resin and use |
| CN102988422A (en) * | 2012-08-23 | 2013-03-27 | 耿福能 | American cockroach nano extract and preparation method thereof |
| CN102988420A (en) * | 2012-08-23 | 2013-03-27 | 耿福能 | Nano periplaneta americana product as well as preparation method and application thereof |
| CN104586897A (en) * | 2014-12-29 | 2015-05-06 | 王帅 | Anti-cancer medicine |
| CN105878289A (en) * | 2015-07-06 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | Periplaneta americana preparation and applications thereof in preparing medicines for treating gastric cancer |
| CN105878290A (en) * | 2015-07-06 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | Periplaneta americana preparation and applications thereof in preparing medicines for treating colon cancer |
| CN105943558A (en) * | 2016-06-21 | 2016-09-21 | 四川好医生攀西药业有限责任公司 | Application of periplaneta americana in preparation of drug for preventing and treating radiation-induced damage |
Non-Patent Citations (6)
| Title |
|---|
| 乔婷婷 等: "美洲大蠊逆转肝癌多药耐药性的研究", 《中国生化药物杂志》 * |
| 于珊珊 等: "美洲大蠊药理作用及临床应用研究", 《辽宁中医药大学学报》 * |
| 倪晶 等: "索拉非尼联合中药治疗原发性肝癌的研究进展", 《东南国防医药》 * |
| 曹隽: "康复新液联合化疗治疗急性白血病的疗效观察", 《中国医药指南》 * |
| 王国泰 等: "松香联合索拉非尼治疗中晚期原发性肝癌疗效评价", 《实用肝脏病杂志》 * |
| 田振国: "《中医临床诊疗指南释义 肛肠疾病分册》", 31 October 2015 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI663981B (en) | Powder having function on regulating gastrointestinal tract and protecting gastric mucosa and the preparation method and application thereof | |
| CN103520151B (en) | γ-and the medical usage of Delta-Tocopherol and its derivative as radioprotectant | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN103877508A (en) | Traditional Chinese medicine composition for treating metrocarcinoma | |
| CN103463554A (en) | Pharmaceutical composition for treating malignant tumor, preparation method and application | |
| CN107693546A (en) | A kind of medicine containing American cockroach and Sorafenib and its application | |
| CN110269897B (en) | Composition for resisting fatigue and improving sleep and application thereof | |
| TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
| CN112274626A (en) | A Chinese medicinal composition for treating cancer | |
| CN108261511B (en) | Composition with weight-losing effect and preparation method and application thereof | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN107714732A (en) | A kind of medicine containing American cockroach and capecitabine and its application | |
| WO2018188548A1 (en) | Traditional chinese medicine composition with hypoglycemic effect | |
| CN104435657B (en) | A kind of medicine for preventing and treating prostate cancer endocrine therapy side effect and preparation method thereof | |
| CN104207130B (en) | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition | |
| CN108079055B (en) | Combination of traditional Chinese medicine composition and sorafenib and application of combination in preparation of medicine for treating liver cancer | |
| CN112494598B (en) | Effective part composition for treating pharyngitis and application thereof | |
| CN108653554B (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN113855734B (en) | Medicine for treating diarrhea and preparation method thereof | |
| CN107349303B (en) | Traditional Chinese medicine composition for treating chronic chest pain and application thereof | |
| CN101244170B (en) | Medicament for treating children's exogenous cough and preparation method | |
| CN107019771A (en) | A kind of antineoplastic Chinese medicine composition | |
| CN107158062B (en) | Tumor adjuvant therapy medicine and application thereof | |
| CN105709228A (en) | Medicine composition used for treating myocardial ischemia and preparation method thereof | |
| CN108210493B (en) | Pharmaceutical composition for improving gastric precancerous lesion and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |
|
| RJ01 | Rejection of invention patent application after publication |